SB-1317

SB-1317 is a multi-kinase inhibitor. It inhibits Cdk1, -2, -3, -5, and -9 (IC50s = 3-9 nM), as well as JAK family kinases (IC50s = 14-59 nM), wild-type and mutant FLT3s (IC50s = 19-27 nM), and Src family kinases (IC50s = 11-15 nM). SB-1317 inhibits proliferation in a panel of 12 liquid and six solid tumor cell lines (mean IC50 = 0.19 µM). It induces cell cycle arrest at the G1 phase and apoptosis in MV4-11 acute myeloid leukemia (AML) cells. SB-1317 (10, 20, and 40 mg/kg) reduces tumor volume and increases survival in an MV4-11 mouse xenograft model.Formal Name: 14-methyl-20-oxa-5,7,14,27-tetraazatetracyclo[19.3.1.12,6.18,12]heptacosa-1(25),2,4,6(27),8,10,12(26),16,21,23-decaene. CAS Number: 937270-47-8. Synonyms: TG02, Zotiraciclib. Molecular Formula: C23H24N4O. Formula Weight: 372.5. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMF: slightly soluble, DMSO: 30 mg/ml. lambdamax: 282 nm. SMILES: CN(CC1=CC=CC(/N=C2N=CC=C3N/2)=C1)C/C=C/CCOC4=CC=CC3=C4. InChi Code: InChI=1S/C23H24N4O/c1-27-13-3-2-4-14-28-21-10-6-8-19(16-21)22-11-12-24-23(26-22)25-20-9-5-7-18(15-20)17-27/h2-3,5-12,15-16H,4,13-14,17H2,1H3,(H,24,25,26)/b3-2+. InChi Key: VXBAJLGYBMTJCY-NSCUHMNNSA-N.